SYK

Stryker Corporation

HealthcareMedical DevicesNASDAQ

$305.09

-$8.18 (-2.68%)today

Conviction

0/ 10

Fair Value$423.73

Upside+38.89%

Signal0

Market Cap$126.8B

52W Range$319.32–$404.87

Next EarningsApr 30

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$204.61

Current Price$335.67

Upside / Down-39.0%

P(Undervalued)0.7%

P(20%+ Up)0.0%

P(15%+ Down)93.6%

Fair Value Distribution — percentile bands

0.7% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

19.7%/yr

±5.6% · revenue growth to justify current price

FCF-Based Reverse DCF

17.9%/yr

±3.3% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Quick Take

Stryker Corporation operates as a medical technology company in the United States and internationally.

Trailing P/E39.5x

Forward P/E19.8x

P/S5.1x

EPS (TTM)$8.39

Analyst Target$423.73

Analyst Upside38.9%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kFeb 28

Conviction: unchanged

SYK FY2025 10-K: Inari Acquisition Reshapes Portfolio; Mako Keeps Winning

Stryker delivered 11.2% revenue growth to $25.1B in FY2025. Organic constant-currency growth of ~9.9% demonstrates durable competitive positioning. MedSurg/Neuro grew 15.7% (Inari acquisition drove Va...